Search for a trial

Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia

This study has been transitioned to CTIS with ID 2024-518855-43-00 check the CTIS register for the current data. Primary objective: To evaluate the effect of SGLT2 inhibition with dapagliflozin 10 mg on serum magnesium in diabetic and non-diabetic…

An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from 1 to 18 years of age with chronic kidney disease and proteinuria

This study has been transitioned to CTIS with ID 2023-504885-50-00 check the CTIS register for the current data. A study to learn more about how safe the study treatment finerenone is inlong-term use when taken with an ACE inhibitor or angiotensin…

Long-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.

This study has been transitioned to CTIS with ID 2024-512580-31-00 check the CTIS register for the current data. PrimaryTo evaluate the long-term safety and tolerability of TX200-TR101 up to 15 years post-TX200-TR101 infusion/baseline.SecondaryTo…

Protein supplementation and exercise training to increase muscle protein synthesis rates in patients with advanced chronic kidney disease

1. To assess whether the skeletal muscle protein fractional synthesis rate as measured by the deuterated water method is different during a 1-week habitual lifestyle period when compared to a 1-week period with resistance-type exercise and protein…

The RENAL LIFECYCLE trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease

This study has been transitioned to CTIS with ID 2023-508389-13-00 check the CTIS register for the current data. To determine whether dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of kidney failure…

The role of gutmicrobiota composition, epigenetics and autoimmunity in the development and treatment of vasculitis; the VASKIR biobank

Primary Objective: Primary: Gut microbiota (oral and fecal) and nasal microbiota composition in relation to autoimmunity status (antibodies (ANA, ANCA) and HLA subtype) and inflammatory functional assays as well as disease activity parameters in…

Diseasy Severity in patients with heterozygous COL4A3 or COL4A4 pathogenic Variants and Exploration of Risk factors.

To accomplish this aim we will address the following objectives:1. Define kidney disease heterogeneity within and between families carrying heterozygous COL4A3/COL4A4 pathogenic variants and evaluate hearing loss as non-renal phenotype;2. Analyze…

PREhabilitation of CAndidates for REnal Transplantation: A Hybrid Study

To examine the effect of a multi-modal prehabilitation program on frailty and other indicators of physical and psychological fitness of KTCs during the waiting-list period and its optimal implementation in a real-world situation.

An Integrated Pharmacokinetic and Safety Open-label Basket Trial of Daprodustat for the Treatment of Anemia Associated with Chronic Kidney Disease in Male and Female Children and Adolescents Aged 3 Months to Under 18 Years Requiring or Not Requiring Dialysis.

Primary objectives: - Describe the safety of daprodustat, overall (all ages) and in each age group.Secondary objectives:- Describe changes in other parameters relevant to safety, overall and in each age group.- Describe the effect of daprodustat on…

Decline in renal concentration ability in lithium treated patients

- to explore the decline in renal concentration ability (RCA) in a Dutch population of lithium treated patient - to explore the decline in kidney function

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glomerulonephritis

This study has been transitioned to CTIS with ID 2023-509343-27-00 check the CTIS register for the current data. Participants enrolling from study CLNP023B12301 or CLNP023B12302• Primary Objective: To evaluate the long-term safety and tolerability…